Mary Pieper - Editorial Team
Mary Pieper- author
Mary Pieper is a seasoned journalist, focusing on asbestos awareness and legal and medical issues. She earned her Bachelor's in English with a minor in Journalism from the University of Northern Iowa. Mary's extensive experience includes nearly 20 years as a reporter at the Globe Gazette in Mason City, Iowa, demonstrating her commitment to impactful journalism.
Author Posts
According to an analysis performed by Mesowatch, the number of senior women in the United States dying from mesothelioma...
November 9, 2024
4 min read
Lung cancer remains one of the most formidable public health challenges in the United States, with thousands of new case...
November 9, 2024
5 min read
What if a technology could look inside the human body not just to see what our organs looked like, but to track their pr...
August 15, 2024
4 min read
A recent study provides preclinical evidence that treating pleural mesothelioma with a DNA hypomethylating agent (DHA) i...
August 12, 2024
2 min read
Bloomberg reported Monday that more than 75% of the plaintiffs who filed lawsuits against Johnson & Johnson claimin...
August 12, 2024
2 min read
A jury trial began in South Carolina this week to determine if a man’s use of asbestos-contaminated Johnson & Johns...
August 12, 2024
3 min read
A jury ordered Avon Products, Inc. to pay $24.4 million Friday to the family of a man who developed cancer decades after...
July 29, 2024
2 min read
A bipartisan group of lawmakers proposed legislation on Capitol Hill Tuesday to end the “Texas Two-Step,” a bankruptcy m...
July 25, 2024
2 min read
Johnson & Johnson has proposed a $505 million settlement with two bankrupt mining companies that supplied J&J...
July 17, 2024
2 min read
A federal court upheld an $8 million verdict Thursday against BNSF Railway over the deaths of two former residents of Li...
July 15, 2024
2 min read
The World Health Organization on Friday stated talc is “probably carcinogenic,” based on a study by the WHO’s Internatio...
July 8, 2024
3 min read
Frontiers in Oncology provisionally accepted a case report Friday suggesting the use of first-line nivolumab and ipilimu...
July 5, 2024
2 min read
Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.
CONTACT US
Email: support@mesowatch.com
Phone: (866) 402-1000
Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251
Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer